Author

Xinlei Cai

University of Chinese Academy of SciencesPrimary ORCID profile (0009-0005-4295-6371 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Xinlei CaiiD1 paper · University of Chinese Academy of Sciences

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Hongbin JiiD· 1 shared Liang CheniD· 1 shared Luonan CheniD· 1 shared Meiting YueiD· 1 shared Shijie TangiD· 1 shared Yikai Zhao· 1 shared Zhen Qin· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Hongbin JiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer

Meiting Yue, Zhen Qin, Shijie Tang, Xinlei Cai, Yikai Zhao, Liang Chen, Luonan Chen, Hongbin Ji

This study identifies PIK3CA mutations as drivers of cachexia in EGFR-mutant lung cancer, showing that osimertinib can mitigate cachexia but chemotherapy fails, with aspirin offering a potential treatment.

bioRxiv · Jan 17, 2025 · PreprintCancer Biology